All In Biotech

Drug Trial Radar · NCT00374322

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer

Last checked: Nov 20, 2026Latest source record: Aug 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,166 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,166

Actual

Start

Aug 2006

Primary completion

Sep 2011

Study completion Jul 2013

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Sep 11, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate and compare the safety and efficacy of an oral dual tyrosine kinase inhibitor, lapatinib, versus placebo in women with early-stage ErbB2-overexpressing breast cancer who have completed their primary neoadjuvant or adjuvant chemotherapy and have no clinical or radiographic evidence of disease.

Conditions

  • Neoplasms, Breast

Interventions

  • lapatinibDrug

    Lapatinib 1500 mg (6 tablets) daily for 12 months

  • placeboOther

    6 tablets daily for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])Time frame: From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])

Locations

439 sites in 33 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tuscaloosa, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Sedona, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Fayetteville, Arkansas

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Gilroy, California

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    La Verne, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    Rancho Mirage, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Fairfield, Connecticut

  • GSK Investigational Site

    Norwalk, Connecticut

  • GSK Investigational Site

    Torrington, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Boca Raton, Florida

  • GSK Investigational Site

    Boynton Beach, Florida

  • GSK Investigational Site

    Gainesville, Florida

  • GSK Investigational Site

    New Port Richey, Florida

  • GSK Investigational Site

    Ocala, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Port Saint Lucie, Florida

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Marietta, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Joliet, Illinois

  • GSK Investigational Site

    Park Ridge, Illinois

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Ames, Iowa

  • GSK Investigational Site

    Sioux City, Iowa

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Marrero, Louisiana

Showing 40 of 439 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.